Biohaven (NYSE:BHVN) Releases Quarterly Earnings Results, Misses Expectations By $1.92 EPS

Biohaven (NYSE:BHVN) issued its earnings results on Thursday. The company reported ($3.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92), Zacks reports.

Biohaven Trading Up 6.3 %

NYSE BHVN traded up $2.29 during trading hours on Friday, hitting $38.91. The company’s stock had a trading volume of 854,535 shares, compared to its average volume of 1,216,025. The company has a market capitalization of $3.44 billion, a PE ratio of -5.70 and a beta of 1.32. Biohaven has a 52 week low of $16.45 and a 52 week high of $62.21. The company’s 50-day simple moving average is $35.65 and its two-hundred day simple moving average is $42.77.

Insider Transactions at Biohaven

In related news, Director John W. Childs purchased 28,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was acquired at an average cost of $35.58 per share, with a total value of $996,240.00. Following the transaction, the director now owns 2,311,341 shares of the company’s stock, valued at approximately $82,237,512.78. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Biohaven news, Director John W. Childs purchased 28,500 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average cost of $35.17 per share, with a total value of $1,002,345.00. Following the completion of the transaction, the director now owns 2,283,341 shares of the company’s stock, valued at approximately $80,305,102.97. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John W. Childs acquired 28,000 shares of the business’s stock in a transaction on Thursday, May 30th. The stock was acquired at an average cost of $35.58 per share, for a total transaction of $996,240.00. Following the transaction, the director now owns 2,311,341 shares of the company’s stock, valued at approximately $82,237,512.78. The disclosure for this purchase can be found here. Insiders purchased a total of 84,900 shares of company stock valued at $3,011,613 over the last ninety days. 16.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BHVN. Morgan Stanley initiated coverage on shares of Biohaven in a research note on Wednesday, July 24th. They issued an “overweight” rating and a $58.00 price objective on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $59.00 price target on shares of Biohaven in a research note on Tuesday, June 18th. UBS Group raised their price objective on Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. HC Wainwright reiterated a “buy” rating and issued a $59.00 target price on shares of Biohaven in a report on Thursday, May 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a report on Thursday, May 30th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $55.13.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.